ALPN News and Press, Alpine Immune Sciences Inc. From 08/18/19

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had an active week, opening at 3,298.28 points on Monday (August 12) and reaching a high of 3,338.66 points on Tuesday (August 13). Throughout the rest of the period, the index continued dropping before settling at 3,290.75 points as of 1:1...

Gainers:  Plus Therapeutics (NASDAQ: PSTV ) +213% . Mmtec (NASDAQ: MTC ) +33% . Solid Biosciences (NASDAQ: SLDB ) +32% . IMAC Holdings (NASDAQ: IMAC ) +31% . Seadrill Limited (NYSE: SDRL ) +30% . StoneMor Partners L.P. (NYSE: STON ) +27% . Alpine Immune Sciences (NASDAQ: ALPN ) ...

Alpine Immune Sciences (NASDAQ: ALPN ): Q2 GAAP EPS of -$0.64 beats by $0.04 . More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

ALPN-101 Progresses to Multiple-Ascending Dose Cohorts of Phase I Study ALPN-202 Submission for Clinical Trial Authorization Anticipated by Year End 2019 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the 2019 Wedbush Securities PacGrow Healthcare Conference...

The following slide deck was published by Alpine Immune Sciences, Inc. in conjunction with this Read more ...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the appointment of Wayne Gombotz, PhD as Chief Technology Officer. Dr. Gombotz has m...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in three upcoming investor conferences in June. J...

Adaptimmune ( ADAP +3.7% ) will collaborate with Alpine Immune Sciences ( ALPN +4.4% ) to develop next-generation SPEAR T-cell products based on the latter's secreted and transmembrane immunomodulatory protein (SIP and TIP) technology . More news on: Adaptimmune Therapeutics plc, Al...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 15, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Alpine Immune Sciences, Inc., Seattle, WA, (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatmen...